Zalicus to Ring NASDAQ Closing Bell

- Celebrates Name and Ticker Symbol Change -

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced that Mark Corrigan, President and CEO is scheduled to preside over the NASDAQ closing bell ceremony on Friday, September 17, 2010 at 4:00 p.m. to celebrate the Company’s recent name and ticker symbol change. The Company’s common stock began trading on the NASDAQ Global Market on Thursday, September 9, 2010 under the ticker symbol ZLCS. Interested parties may access the NASDAQ MarketSite webcam feed to view the ceremony live by launching this link, http://www.nasdaq.com/about/marketsitetowervideo.asx at 3:50 p.m.

Mark H.N. Corrigan, President and CEO of Zalicus Inc. said, “It’s an honor to ring the NASDAQ closing bell and to celebrate our evolution into a new, multi-dimensional company following the completed integration of Neuromed and CombinatoRx and the commercial launch of Exalgo by Covidien. Under the Zalicus name we look forward to bringing innovative treatments to patients using the expertise and focus of the merged company.

About Zalicus

Zalicus Inc. (NASDAQ: ZLCS) is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases. Zalicus applies its selective ion-channel modulation platform and its combination high throughput screening capabilities to discover innovative therapeutics for itself and its collaborators. To learn more about Zalicus, please visit www.zalicus.com.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning Zalicus, the Zalicus selective ion channel modulation technology, Zalicus’ combination drug discovery technology, cHTS, and its other business plans. These forward-looking statements about future expectations, plans, objectives and prospects of Zalicus may be identified by words like "believe," "expect," "may," "will," "should," "seek," “plan” or “could” and similar expressions and involve significant risks, uncertainties and assumptions, including risks related to the development and regulatory approval of Zalicus’s product candidates, the unproven nature of the Zalicus drug discovery technologies, and those other risks that can be found in the "Risk Factors" section of Zalicus's annual report on Form 10-K on file with the Securities and Exchange Commission and the other reports that Zalicus periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Zalicus contemplated by these forward-looking statements. These forward looking statements reflect management’s current views and Zalicus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law.

(c) 2010 Zalicus, Incorporated. All rights reserved.



CONTACT:

Zalicus Inc.
Justin Renz, 617-301-7575
Senior Vice President, CFO
[email protected]
or
Gina Nugent, 857-753-6562
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Professional Services  Finance

MEDIA:

Logo
 Logo

Suggested Articles

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.

The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.